Prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib

被引：0

作者：

Hochmair, Maximilian ^{[1
,2
]}

Schwab, Sophia ^{[1
,2
]}

Burghuber, Otto ^{[1
,2
]}

Koger, Renate ^{[1
,2
]}

Setinek, Ulrike ^{[1
,2
]}

Cseh, Agnieszka ^{[1
,2
]}

Fritz, Richard ^{[1
,2
]}

Buder, Anna ^{[3
]}

Filipits, Martin ^{[3
]}

机构：

[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria

[3] Med Univ Vienna, Inst Canc Res, Dept Med 1, Comprehens Canc Ctr, Vienna, Austria

来源：

WIENER KLINISCHE WOCHENSCHRIFT | 2017年 / 129卷 / 19-20期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P55

引用

页码：776 / 776

页数：1

共 50 条

[1] Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
Hochmair, M.
Schwab, S.
Burghuber, O.
Koger, R.
Setinek, U.
Cseh, A.
Fritz, R.
Buder, A.
Filipits, M.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2136 - S2136
[2] Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Hochmair, Maximilian J.
Buder, Anna
Schwab, Sophia
Burghuber, Otto C.
Prosch, Helmut
Hilbe, Wolfgang
Cseh, Agnieszka
Fritz, Richard
Filipits, Martin
TARGETED ONCOLOGY, 2019, 14 (01) : 75 - 83
[3] Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Maximilian J. Hochmair
Anna Buder
Sophia Schwab
Otto C. Burghuber
Helmut Prosch
Wolfgang Hilbe
Agnieszka Cseh
Richard Fritz
Martin Filipits
Targeted Oncology, 2019, 14 : 75 - 83
[4] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
Zhao, S.
Jiang, T.
Li, X.
Zhao, C.
Su, C.
Ren, S.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
[5] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Zhang, X.
Wu, Y-L.
Chen, Y.
Zhang, H.
Wu, G.
Lu, Y.
Liang, Z.
Hu, Y.
Cheng, Y.
Wang, J.
Ying, J.
Liu, W.
Liang, Z.
ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
[6] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
Li, C.
Liu, H.
Zhang, B.
Zhang, Z.
Su, Y.
Wang, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
[7] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Zhao, Sha
Li, Xuefei
Zhao, Chao
Jiang, Tao
Jia, Yijun
Shi, Jinpeng
He, Yayi
Li, Jiayu
Zhou, Fei
Gao, Guanghui
Li, Wei
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
LUNG CANCER, 2019, 128 : 33 - 39
[8] A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
Jiang, R.
Wang, X.
Wang, L.
Huang, D.
Ding, C.
Wang, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S346 - S347
[9] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
Yoshimura, Naruo
Takahashi, Hidenori
Kurosawa, Emiko
Tanaka, Akiko
Ebina, Masahito
Ohrui, Takashi
ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
[10] Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation
Miyazaki, Kunihiko
Tamura, Tomohiro
Kaburagi, Takayuki
Saito, Kazuhito
Inagaki, Masaharu
Yamashita, Takaaki
Ichimura, Hideo
Nawa, Takeshi
Endo, Takeo
Hayashihara, Kenji
Kimura, Masaki
Kurishima, Koichi
Nakamura, Hiroyuki
Furukawa, Kinya
Kikuchi, Norihiro
Satoh, Hiroaki
Hizawa, Nobuyuki
ANTICANCER RESEARCH, 2018, 38 (09) : 5409 - 5415

← 1 2 3 4 5 →